

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented): A drug complex represented by the following formula:



wherein A is a polymer as a drug carrier comprising a polysaccharide derivative having carboxyl groups; R is a spacer, wherein said spacer is an amino acid or an oligopeptide comprising 2 to 8 amino acids; Y is phenylene group which may be substituted; and Q is a residue of a drug compound.

2. (Canceled)

3. (Previously Presented): The drug complex according to claim 1, wherein R is a spacer comprising peptide-bonded 2 to 8 amino acids.

4. (Previously Presented): The drug complex according to claim 1, wherein Y is p-phenylene group which may be substituted.

5. (Previously Presented): The drug complex according to claim 1, wherein Y is unsubstituted p-phenylene group.

6. (Previously Presented): The drug complex according to claim 1, wherein the polysaccharide derivative having carboxyl groups is a carboxy(C₁₋₄)alkyldextran polyalcohol.

7. (Original): The drug complex according to claim 6, wherein dextran polyalcohol that constitutes the carboxy(C₁₋₄)alkyldextran polyalcohol is dextran polyalcohol which is obtained by treating dextran under conditions that enable substantially complete polyalcoholization.

8. (Previously Presented): The drug complex according to claim 6, wherein the carboxy(C₁₋₄)alkyldextran polyalcohol is carboxymethyldextran polyalcohol.

9. (Previously Presented): The drug complex according to claim 1, wherein the drug compound is an antineoplastic agent or an anti-inflammatory agent.

10. (Previously Presented): The drug complex according to claim 1, wherein the drug compound has an amino group and the amino group is bound to A-R-NH-Y-CH₂-O-CO- by the amino group.

11. (Original): The drug complex according to claim 10, wherein the drug compound is (1S,9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13(9H,15H)-dione.

12. (Previously Presented): The drug complex according to claim 11, wherein R is -Gly-Gly-Phe-Gly- (SEQ ID NO: 1).

13. (Previously Presented): The drug complex according to claim 11, wherein R is -Gly-Gly-Gly-Phe- (SEQ ID NO: 2).

14. (Previously Presented) A drug delivery system composition comprising a drug complex according to claim 1.

15. (Previously Presented): The drug delivery system composition according to claim 14, wherein the drug compound is (1S,9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-(9H,15H)-dione.

16. (Previously Presented): The drug delivery system composition according to claim 15, wherein R is -Gly-Gly-Phe-Gly- (SEQ ID NO: 1).

17. (Previously Presented): The drug delivery system according to claim 15, wherein R is -Gly-Gly-Gly-Phe- (SEQ ID NO: 2).

18. (Currently Amended): A method of producing a drug complex according to claim 1, comprising reacting a compound represented by the following formula with a drug compound carrier:



wherein R' is a group which comprises one amino acid or peptide-bonded 2 to 8 amino acids and whose N-terminal is protected or not protected; Y is phenylene group which may be substituted; and Q is a residue of a drug compound.

19. (Previously Presented): The compound according to claim 18, wherein Y is unsubstituted p-phenylene group, R' is a group represented by H-Gly-Gly-Phe-Gly- (SEQ ID NO: 1), and the drug compound is (1S,9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-(9H,15H)-dione.

20. (Previously Presented): The compound according to claim 18, wherein Y is unsubstituted p-phenylene group, R' is a group represented by H-Gly-Gly-Gly-Phe- (SEQ ID NO: 2), and the drug compound is (1S,9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-(9H,15H)-dione.

21. (Original): A compound represented by the following formula:



wherein A is a polymer as a drug carrier; R is a spacer, wherein said spacer is an amino

acid or an oligopeptide comprising 2 to 8 amino acids; Y is phenylene group which may be substituted; and X is selected from the group comprising hydroxyl group, -O-M wherein M is a protective group for carboxyl group, or an eliminating group.

22. (Canceled)